1. GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.
- Author
-
Pan, Heng-Chih, Chen, Jui-Yi, Chen, Hsing-Yu, Yeh, Fang-Yu, Sun, Chiao-Yin, Huang, Thomas Tao-Min, and Wu, Vin-Cent
- Subjects
GLUCAGON-like peptide-1 receptor ,GLUCAGON-like peptide-1 agonists ,ACUTE diseases ,KIDNEY diseases ,TYPE 2 diabetes ,PEPTIDE receptors ,SEPSIS - Abstract
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes. Here, the authors show that GLP-1 RAs are associated with reduced mortality and improved cardio-renal outcomes in type 2 diabetes patients with acute kidney disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF